Alexandria Real Estate Equities is focusing on “timely execution” in 2026, aiming for $2.9 billion in dispositions and reduced capex. Q4 saw $1.5 billion in dispositions, 1.2 million sq ft leased, and 90.9% occupancy. Outlook expects occupancy to temporarily dip due to expirations before improving in H2 with a strong balance sheet.

Executives emphasize dispositions, balance sheet flexibility, and leasing in 2026. Q4 showed $1.5 billion in dispositions and 1.2 million sq ft leased. Full-year FFO adjusted was $9.01. Leasing volumes increased, but rental rates faced pressure. Occupancy was at 90.9%, with leases for 900,000 sq ft expected in Q3 2026.

Anticipated occupancy dip in early 2026 due to expirations and tenant negotiations. Same-property NOI down 6% in Q4 and expected to decrease 8.5% in 2026. Company focuses on large-scale non-core dispositions and recognized $1.45 billion in impairments in Q4. Balance sheet remains strong with $5.3 billion liquidity.

Management emphasizes reducing capital expenditures and dispositions in 2026. Q4 saw $1.5 billion in dispositions and 1.2 million sq ft leased. Occupancy at 90.9% with leases for 900,000 sq ft in Q3 2026. Company expects non-core assets to comprise 65-75% of dispositions, recognizing $1.45 billion in impairments in Q4.

Leasing market cautious with elongated decision timelines. Public biotech leasing remains slow. Concessions stable, but free rent elevating. Decision to lease Fenway asset as office space explained. Alexandria Real Estate Equities specializes in collaborative life science and technology campuses, supporting research and innovation.

Founded in 1994, Alexandria Real Estate Equities owns, develops, and manages life science and technology campuses. The company’s properties provide specialized space for biotech, pharmaceutical, academic, and related industries. Diversified portfolio of campuses across North America and Europe.

Read more at Yahoo Finance: Alexandria Real Estate Equities Q4 Earnings Call Highlights